Diseases caused by drug resistant bacteria are becoming a pressing public health threat due to a lack of new antibiotics and the evolution of multidrug resistance. Drug resistance is caused by mutant or novel genes known as resistance genes. CRISPR-Cas9 gene editing has been shown in recent studies to successfully edit resistance genes to increase susceptibility to antibiotics. We aim to use bacteriophage M13 to transduce a CRISPR-Cas9 system into nalidixic acid resistant Escherichia coli and resensitize it to nalidixic acid. We aim to improve upon the efficiency of previous studies.